It has been suggested that PD-L1 expression, high tumor mutational burden (TMB) which is highly influenced by the epitopes displayed in the human leukocyte antigen (HLA) genes of a tumor, and the presence of CD8+ T cells are prognostic of clinical response to treatment with ICB (6). Here, CD274 is linked to neoplasm.